New strategy sees Genmab land antibody research deal with Seattle Genetics

Genmab's recently appointed CEO Professor Jan van de Winkel has wasted little time in stamping his authority on the struggling Danish biotech, announcing a new corporate strategy to reduce operating costs by 20% next year and signing a research deal with Seattle Genetics.